The Israeli Drug Basket provides subsidized access to bone-building biological treatments for severe osteoporosis. Coverage includes innovative medications like romosozumab and teriparatide for high-risk patients. The state also subsidizes essential diagnostics like DEXA scans and supportive physical therapy at JCI-accredited facilities.
- Biological medications: Evenity (romosozumab) is covered for patients at high fracture risk.
- Bone-forming agents: Forteo (teriparatide) remains a subsidized option for up to 2 years.
- Diagnostic services: Health funds cover bone density scans (DEXA) for routine screening.
- Surgical support: Procedures like kyphoplasty for vertebral fractures are included in the basket.
Bookimed Expert Insight: Patients should note that top hospitals like Sourasky and Hadassah manage over 1,000,000 patients annually. This high volume ensures specialists have deep experience with the specific eligibility criteria for newer biologicals. Coordination between endocrinology and orthopedics at these centers helps secure approvals for advanced bone-building regimens.
Patient Consensus: Patients note that while the basket lowers medication costs, getting the actual approval for high-end biologicals requires detailed documentation of previous treatment results. Most emphasize that having a neurologist or orthopedist advocate for your specific case makes a difference.